The discovery of genetic mapping led to a considerable expansion of medical data knowledge or ‘big data,’ which Foley partner Richard Kaufman suggests can be properly analyzed to improve drug discovery success and reduce the cost of developing a drug. He compares genetic mapping to an exquisite tailoring of one’s personal biology that holds the potential to make drugs developed using this data much more effective and ultimately may lead to better outcomes for patients.
People
Related News
16 May 2025
In the News
Foley's East Coast Litigation Additions Highlighted in Legal Press
Foley & Lardner LLP partners Kenneth Breen, Phara Guberman, and Joseph Dowdy are featured across legal press for their recent move to the firm.
16 May 2025
In the News
Foley Attorneys Assess AI Use in Clinical Trials
Foley & Lardner LLP partners Monica Chmielewski and Kyle Faget shared insights on the growing adoption of artificial intelligence in clinical trials in the Clinical Trials Arena article, "Are regulators keeping pace with AI adoption in clinical trials?"
15 May 2025
In the News
Grace Fucci Publishes on Sustainability in Luxury Fashion
Foley & Lardner LLP associate Grace Fucci explores the intersection of luxury fashion and sustainability in The Global Legal Post article, "Can luxury fashion houses join the sustainability discussion?"